Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)
Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –
Amneal Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Amneal Pharmaceuticals's operating margin for the twelve months ending Jun 30, 2026 was 14.6%. For fiscal 2025 it was 13.1%, against 8.9% the year before. The highest annual figure on record is 28.0% in fiscal 2016.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.1% | +4.1 |
| FY2024 | Dec 31, 2024 | 8.9% | +0.4 |
| FY2023 | Dec 31, 2023 | 8.5% | +12.8 |
| FY2022 | Dec 31, 2022 | -4.3% | −11.6 |
| FY2021 | Dec 31, 2021 | 7.3% | +2.7 |
| FY2020 | Dec 31, 2020 | 4.6% | +19.9 |
| FY2019 | Dec 31, 2019 | -15.3% | −14.1 |
| FY2018 | Dec 31, 2018 | -1.2% | −24.9 |
| FY2017 | Dec 31, 2017 | 23.7% | −4.3 |
| FY2016 | Dec 31, 2016 | 28.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 16.3% | +0.9 |
| Q1 FY2026 | Mar 31, 2026 | 19.6% | +5.2 |
| Q4 FY2025 | Dec 31, 2025 | 13.8% | +3.4 |
| Q3 FY2025 | Sep 30, 2025 | 9.0% | −3.7 |
| Q2 FY2025 | Jun 30, 2025 | 15.4% | +1.8 |
| Q1 FY2025 | Mar 31, 2025 | 14.4% | +16.1 |
| Q4 FY2024 | Dec 31, 2024 | 10.4% | +8.1 |
| Q3 FY2024 | Sep 30, 2024 | 12.6% | +0.4 |
| Q2 FY2024 | Jun 30, 2024 | 13.6% | +0.2 |
| Q1 FY2024 | Mar 31, 2024 | -1.6% | −7.8 |
| Q4 FY2023 | Dec 31, 2023 | 2.3% | −3.6 |
| Q3 FY2023 | Sep 30, 2023 | 12.2% | +4.1 |
| Q2 FY2023 | Jun 30, 2023 | 13.4% | +48.9 |
| Q1 FY2023 | Mar 31, 2023 | 6.2% | +1.5 |
| Q4 FY2022 | Dec 31, 2022 | 5.9% | +3.8 |
| Q3 FY2022 | Sep 30, 2022 | 8.1% | +2.7 |
| Q2 FY2022 | Jun 30, 2022 | -35.5% | −48.1 |
| Q1 FY2022 | Mar 31, 2022 | 4.7% | −4.6 |
| Q4 FY2021 | Dec 31, 2021 | 2.1% | −1.9 |
| Q3 FY2021 | Sep 30, 2021 | 5.4% | +4.9 |
| Q2 FY2021 | Jun 30, 2021 | 12.5% | +10.2 |
| Q1 FY2021 | Mar 31, 2021 | 9.3% | −2.3 |
| Q4 FY2020 | Dec 31, 2020 | 4.0% | +9.8 |
| Q3 FY2020 | Sep 30, 2020 | 0.5% | +30.1 |
| Q2 FY2020 | Jun 30, 2020 | 2.3% | +7.0 |
| Q1 FY2020 | Mar 31, 2020 | 11.6% | +32.7 |
| Q4 FY2019 | Dec 31, 2019 | -5.8% | −10.5 |
| Q3 FY2019 | Sep 30, 2019 | -29.7% | −45.3 |
| Q2 FY2019 | Jun 30, 2019 | -4.7% | +39.1 |
| Q1 FY2019 | Mar 31, 2019 | -21.2% | −44.2 |
| Q4 FY2018 | Dec 31, 2018 | 4.7% | −22.3 |
| Q3 FY2018 | Sep 30, 2018 | 15.6% | −15.3 |
| Q2 FY2018 | Jun 30, 2018 | -43.8% | −60.9 |
| Q1 FY2018 | Mar 31, 2018 | 23.1% | – |
| Q4 FY2017 | Dec 31, 2017 | 26.9% | – |
| Q3 FY2017 | Sep 30, 2017 | 30.9% | – |
| Q2 FY2017 | Jun 30, 2017 | 17.2% | – |
See a number that looks wrong?